EFFICACY AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BODY WEIGHT AND CARDIOMETABOLIC PARAMETERS IN INDIVIDUALS WITH OBESITY AND WITHOUT DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Descargar Publicación
A new dawn of managing cardiovascular risk in obesity: the importance of combining lifestyle intervention and medication La FDA aprueba el ensayo de Veru con Enobosarm para tratar la pérdida muscular asociada con medicamentos para bajar de peso